News & Updates

Adult men with erectile dysfunction may benefit from diet- and exercise-based interventions, which in a recent study have shown to yield modest but significant improvements in erectile function.

Updated results from the phase III PULSAR trial show that intravitreal (IVT) aflibercept 8 mg, when administered at extended dosing intervals of up to 20 weeks, led to visual gains and anatomic improvements comparable to the 2-mg dose, with no new safety concerns over 96 weeks, in treatment-naïve individuals with neovascular age-related macular degeneration (nAMD).

Individuals with overweight or obesity, as well as those who are underweight, are predisposed to limitations in activities of daily living (ADL), reveals a study.